New platform for cellular engineering launched

Cell-based medicines and life sciences company MaxCyte has launched a new technology platform called ExPERT.

These instruments – the ATx, STx and GTx – aiming to represent the next generation of clinically validated, Flow Electroporation technology for complex cellular engineering.

With these additions to the product portfolio, MaxCyte continues its uncompromising focus on high performance cellular editing, while delivering feature enhancements that will enable customers to use a single unifying technology, from concept to commercialisation. ExPERT introduces new updated software, a touch-screen user interface and other features with the aim of improving user experience. The combination of the new instruments, together with the launch of a new range of processing assemblies, aims to enable customers to standardise on a single, unifying technology from early research through to clinical and commercial use.

Brad Calvin, executive vice president of global commercial operations for MaxCyte said: “The ExPERT instrument family is the result of extensive customer research into feature design, functionality and performance that are considered critical to enabling the next generation of cellular therapies. Creating cellular editing platforms standardised on a single, scalable, high performance technology can assist the industry in accelerating timelines, reducing costs and achieving milestones critical to the translation of this promising new generation of cellular therapies.”

The ExPERT ATx, STx and GTx build on the technology foundation that has been the core of MaxCyte’s historical instrument platforms.

Doug Doerfler, MaxCyte’s president and CEO said: “We are proud to announce the launch of our next-generation ExPERT brand of instruments. We are committed to continually investing in our platform and delivering the essential tools, product features and technology performance that are critical to the advancement of promising new cellular therapeutics, which provide hope to many patients with previously incurable or life-threatening diseases.”